The collaborative effort between Protagonist Therapeutics and Takeda Pharmaceutical to develop rusfertide, an injectable drug aimed at treating polycythemia vera, has achieved a significant milestone. Polycythemia vera is a rare blood disorder marked by a proliferation of red blood cells that can
Antibody-drug conjugates (ADCs) are emerging as a groundbreaking approach in oncology, offering the potential to revolutionize cancer treatment through targeted and effective therapies. This innovation combines the precision of targeted antibodies with the potent cell-killing ability of
The recent announcement by Bayer AG and BlueRock Therapeutics LP marks a significant milestone in the development of cell therapies aimed at vision restoration. The FDA has granted Fast Track designation to OpCT-001, a stem cell therapy designed to treat primary photoreceptor diseases such as
Emalex Biosciences recently shared tremendous news regarding their latest breakthrough in the treatment of Tourette syndrome. The company announced promising topline results from its Phase 3 registrational study of ecopipam, a novel dopamine-1 receptor antagonist. This milestone could position
The recent FDA Fast Track designation for BioRestorative Therapies' BRTX-100 program marks a significant milestone in the treatment of chronic lumbar disc disease (cLDD). Given the debilitating nature of cLDD and its prevalence among middle-aged Americans, this development has sparked
The possibility of creating complex three-dimensional human tissues from diverse biological materials has always been an intriguing concept within medical research. The groundbreaking innovation known as the Electrospider, developed by Bio3DPrinting, a spinoff from Italy's University of Pisa,
